Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 15, 2008. The document serves as a report of a specific corporate action regarding share repurchases and cancellation, rather than a comprehensive financial results report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,196.23 pence per share.
Material Changes
- Share Repurchase: On December 15, 2008, the Company purchased 1,300,000 Ordinary shares of 25 pence each.
- Share Cancellation: The repurchased shares were cancelled immediately.
- Treasury Holdings: Following the cancellation, the Company holds 474,194,158 shares in Treasury, representing 9.14% of total voting rights.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) is 5,189,939,523.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a procedural announcement confirming compliance with shareholder authority granted at the Annual General Meeting on May 21, 2008, and adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,189,939,523) for calculating disclosure thresholds under FSA rules.
- Confirm the Treasury share count (474,194,158) and its percentage of voting rights (9.14%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for full financial statements.